Intel’s AI Pivot and Oil Rally Shake Markets

Don’t Stop Here

More To Explore

PBM: Patient Dosing Begins in NPX-5 Phase IIb Trial!

Overview Psyence Biomedical Ltd. (Nasdaq: PBM) is a clinical-stage biopharma company focusing on psychedelic therapeutics, notably nature-derived psilocybin. On April 23, 2026, the company announced